Drug Profile
Selumetinib - AstraZeneca
Alternative Names: AR 00142886; AR 142886 X; ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; KOSELUGO; MK 5618; NSC-748727; Selumetinib hydrogen sulfateLatest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; AstraZeneca; Cancer Research UK; Merck & Co; Merck Sharp & Dohme Corp.; National Cancer Institute (USA); University of Cambridge; University of Chicago
- Class Amides; Amines; Antineoplastics; Benzimidazoles; Halogenated hydrocarbons; Small molecules
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neurofibromatosis 1
- Phase III Glioma
- Phase II Biliary cancer; Colorectal cancer; Gastric cancer; Histiocytosis; Neurofibromatosis 2; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
- Phase I/II Kaposi's sarcoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase I Myelodysplastic syndromes; Myelofibrosis; Plexiform neurofibroma
- No development reported Pancreatic cancer
- Discontinued Acute myeloid leukaemia; Liver cancer; Malignant melanoma; Multiple myeloma; Thyroid cancer
Most Recent Events
- 09 Dec 2023 Efficacy, Pharmacokinetics and adverse events data from a phase I/II trial in Precursor cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 01 Oct 2023 AstraZeneca completes a phase II trial for Neurofibromatosis 1 (Combination therapy, In adolescents, In adults, In children, In the elderly) in USA (PO) (NCT03433183)
- 15 Aug 2023 AstraZeneca in collaboration with Merck Sharp & Dohme LLC completes a phase I trial in Neurofibromatosis 1 (In children, In adolescents, In adults, In the elderly) and Neurofibroma Plexiform (In children, In adolescents, In adults, In the elderly, Inoperable/Unresectable) in China (PO) (NCT04590235)